Observation on the efficacy and safety of containing Bedaquiline regimen in the treatment of drug-resistant tuberculosis
Objective To evaluate the efficacy and safety of a regimen containing bedaquinoline in the treatment of drug-resistant tuberculosis.Methods 36 patients with drug-resistant TB who received containing Bedaquinoline-resistant regimen in Kunming Third People's Hospital from August 2018 to March 2020 were studied.There were 2 cases of RR-TB(5.6％),5 cases of MDR-TB(13.9％),20 cases of Pre-XDR-TB(55.5％),and 9 cases of XDR-TB(25.0％).The therapeutic effect and safety of the drug-resistant patients receiving treatment were observed.Results 36 cases treated with containing Bedaquiline regimen,of which 22 cases(61.1％)were cured,7 cases(19.4％)completed clinical treatment,1 case(2.8％)failed treatment,2 cases(5.6％)died,and 4 cases(11.1％)were lost to follow-up.QT interval prolongation occurred in 32 cases(88.9％).The difference of QTcF during 2,4,8,12,16,20 and 24 weeks of treatment was statistically significant compared with that before treatment(baseline)(P＜0.01).Conclusions The overall therapeutic effect of the regimen containing Bedaquinoline in the treatment of drug-resistant tuberculosis is good,and no major adverse drug events have occurred,which is worthy of clinical application.
万方数据
维普
